374962
对胍基苯甲酸 盐酸盐
99%
别名:
4-胍基苯甲酸 盐酸盐
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
H2NC(=NH)NHC6H4CO2H · HCl
化学文摘社编号:
分子量:
215.64
UNSPSC Code:
12352100
NACRES:
NA.22
PubChem Substance ID:
EC Number:
255-956-3
Beilstein/REAXYS Number:
3718032
MDL number:
Assay:
99%
Form:
solid
InChI key
YETFLAUJROGBMC-UHFFFAOYSA-N
InChI
1S/C8H9N3O2.ClH/c9-8(10)11-6-3-1-5(2-4-6)7(12)13;/h1-4H,(H,12,13)(H4,9,10,11);1H
SMILES string
Cl[H].NC(=N)Nc1ccc(cc1)C(O)=O
assay
99%
form
solid
mp
285 °C (dec.) (lit.)
storage temp.
2-8°C
General description
4-Guanidinobenzoic acid hydrochloride is a guanidine derivative. Quality standard of 4-guanidinobenzoic acid hydrochloride has been investigated.
Application
4-Guanidinobenzoic acid hydrochloride may be used in ELISA inhibition assay of mouse antiserum. It may be used in the synthesis of human acrosin inhibitor 4′-acetaminophenyl 4-guanidinobenzoate hydrochloride.2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
I Midgley et al.
Xenobiotica; the fate of foreign compounds in biological systems, 24(1), 79-92 (1994-01-01)
1. The metabolic fate of N,N-dimethylcarbamoylmethyl 4-(4-guanidino[14C]benzoyloxy)phenylacetate methanesulphonate (14C-camostat mesylate) was investigated after i.v. administration to man (12-h infusion), and to rat and dog (bolus injection). 2. Renal excretion (mainly in 24 h) accounted for at least 80% dose in
M K Ramjee et al.
Thrombosis research, 98(6), 559-569 (2000-07-19)
Nafamostat mesilate (FUT-175), a synthetic serine protease inhibitor, is active against a number of the serine proteases involved in coagulation. This has been proposed as the basis of its anticoagulant activity. We investigated the reaction of Nafamostat with bovine pancreatic
S Ookawara et al.
European journal of clinical pharmacology, 51(2), 149-151 (1996-01-01)
Nafamostat mesilate, a potent protease inhibitor, is widely used for the treatment of pancreatitis, disseminated intravascular coagulation and as an anticoagulant in haemodialysis. However, hyperkalaemia associated with nafamostat mesilate has been reported. It is thought to be due to decreased
Hepatic and pancreatic metabolism and biliary excretion of the protease inhibitor camostat mesilate.
K Beckh et al.
International journal of pancreatology : official journal of the International Association of Pancreatology, 10(3-4), 197-205 (1991-11-01)
The hepatic metabolism and biliary and pancreatic excretion of the serine protease inhibitor camostat mesilate and its metabolites FOY-251 and GBA were studied in rats in vivo and in in sutu liver-perfusion experiments. After oral feeding (100 mg/kg) and iv
S Muto et al.
British journal of pharmacology, 111(1), 173-178 (1994-01-01)
1. The present experiments were undertaken to determine the mechanism(s) of hyperkalaemia caused by nafamostat mesilate (NM), a serine-protease inhibitor. 2. We investigated the effects of luminal addition of two metabolites of NM, p-guanidinobenzoic acid (PGBA) and 6-amidino-2-naphthol (AN), on
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持